Dr Richter on the Optimal Dosing Schedule of Linvoseltamab in Multiple Myeloma

Joshua Richter, MD, discusses findings from the phase 1/2 LINKER-MM1 trial (NCT03761108) in multiple myeloma.

Related Keywords

,Joshua Richter ,Blavatnik Family Chelsea Medical Center ,Division Of Hematology ,Tisch Cancer Institute ,Medical Oncology ,Multiple Myeloma ,Mount Sinai ,Phase 1 2 Linker Mm1 Trial ,Nct03761108 ,Relapsed Refractory Multiple Myeloma ,2023 International Myeloma Society Annual Meeting ,